Ascentage Pharma’s novel cancer drug, lisaftoclax, was approved by China’s NMPA for CLL and SLL patients who have received previous therapies, including BTK inhibitors. It is the first Bcl-2 inhibitor to receive conditional approval for CLL/SLL in China and the second globally. The drug selectively blocks Bcl-2 to restore normal apoptosis in cancer cells, showing promise in clinical trials for various malignancies.

Ascentage Pharma Group International is a clinical-stage biotech company focused on developing therapies for cancer, chronic hepatitis B virus, and age-related diseases in China. While AAPG has investment potential, some AI stocks may offer greater growth with lower risk. For an undervalued AI stock benefiting from tariffs and onshoring trends, consider the free report on the best short-term AI stock.

Read more at Yahoo Finance: Ascentage Pharma’s Novel Cancer Drug Approved in China